Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMIDATE vs CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction and decongestion of nasal mucosa.
Induction of general anesthesia,Maintenance of anesthesia (as part of balanced anesthesia),Procedural sedation (off-label),Rapid sequence intubation (RSI) (off-label)
Relief of symptoms of seasonal allergic rhinitis such as sneezing, rhinorrhea, and nasal congestion,Relief of nasal congestion due to common cold or upper respiratory allergies
0.2-0.6 mg/kg IV bolus for induction of anesthesia.
1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours; maximum 2 tablets per day.
Terminal elimination half-life: 2.5–4 hours (adults); 1–2 hours (children); Prolonged in hepatic impairment or with continuous infusion.
Cetirizine: terminal half-life ~8.3 hours in healthy adults (prolonged to 20-30 hours in renal impairment). Pseudoephedrine: terminal half-life ~4-8 hours (p H-dependent urinary excretion; prolonged in alkaline urine).
Primarily hepatic via hydrolysis by esterases to inactive metabolites (carboxylic acid and ethanol); also undergoes glucuronidation.
Cetirizine undergoes minimal hepatic metabolism via oxidation to an inactive metabolite, primarily excreted unchanged in urine. Pseudoephedrine is partially metabolized in the liver by N-demethylation to an active metabolite, with about 50-75% excreted unchanged in urine.
Renal: <5% unchanged; Hepatic metabolism to carboxylic acid metabolite (inactive); Metabolite renally eliminated; Fecal: negligible.
Cetirizine: approximately 70% excreted unchanged in urine via glomerular filtration and tubular secretion; about 10% in feces. Pseudoephedrine: 70-90% excreted unchanged in urine; remainder as inactive metabolites.
97–98% bound; Primary binding to albumin; Reduced binding in neonates and hepatic/renal disease.
Cetirizine: 93% bound to albumin. Pseudoephedrine: not significantly protein bound (<10%).
Vd: 2.5–4.5 L/kg; Large Vd indicates extensive tissue distribution (highly lipophilic).
Cetirizine: 0.5-0.8 L/kg (total body water). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
IV: 100%; IM: >90%; Rectal: ~50% (variable).
Cetirizine: oral bioavailability ~70% (not affected by food). Pseudoephedrine: oral bioavailability ~100% (first-pass metabolism minimal).
No adjustment required; pharmacokinetics unchanged in renal impairment.
GFR 30-49 m L/min: 1 tablet every 24 hours. GFR <30 m L/min or dialysis: contraindicated.
No specific guidelines; use with caution in severe hepatic impairment due to potential for decreased clearance.
Child-Pugh A or B: no dose adjustment required. Child-Pugh C: contraindicated due to lack of data.
3-5 mg/kg IV bolus for induction in children; lower doses may be sufficient.
Children <12 years: not approved. Children ≥12 years: same as adult dosing (5 mg/120 mg every 12 hours).
Reduce dose to 0.15-0.3 mg/kg IV bolus due to increased sensitivity and decreased clearance.
Use with caution; start with 1 tablet every 24 hours due to increased sensitivity and risk of anticholinergic effects.
None
None
Suppresses adrenal steroidogenesis via reversible inhibition of 11-beta-hydroxylase (cortisol and aldosterone synthesis) – risk of adrenal insufficiency, especially with prolonged infusion or multiple doses,May cause myoclonus (involuntary muscle movements) during induction,Can produce hypotension less frequently than other induction agents, but still possible,Use caution in patients with adrenal suppression, sepsis, or hepatic impairment,May cause pain on injection (use large vein or consider pretreatment)
Cardiovascular effects: Use with caution in patients with hypertension, cardiovascular disease, or ischemic heart disease due to pseudoephedrine's vasoconstrictive and positive chronotropic effects,Cerebrovascular effects: Pseudoephedrine may cause ischemic colitis, hemorrhagic stroke, or vasospasm; avoid in patients with history of stroke or vasculopathy,Nervous system effects: May cause insomnia, nervousness, or seizure; use with caution in elderly or those with seizure disorders,Renal impairment: Dose adjustment for cetirizine necessary in moderate to severe renal impairment,Drug interactions: Avoid MAO inhibitors or use within 14 days; concomitant use with other sympathomimetics may increase adverse effects
Known hypersensitivity to etomidate or any component of the formulation,Patients with known adrenal insufficiency (relative contraindication due to potential for further suppression)
Hypersensitivity to cetirizine, pseudoephedrine, or any components,Severe hypertension or coronary artery disease,Use of monoamine oxidase inhibitors (MAOIs) currently or within 14 days,Narrow-angle glaucoma,Urinary retention,Severe renal impairment (Cr Cl <10 m L/min) for cetirizine component
None known. However, because etomidate is administered intravenously in a fasting state prior to procedures, food intake is restricted per standard pre-procedural fasting guidelines (typically NPO for 6-8 hours).
No significant food interactions. Avoid concurrent use of caffeine or other stimulants (e.g., coffee, tea, energy drinks) as pseudoephedrine may additive CNS stimulation. Take without regard to meals; fatty meals may delay absorption of cetirizine but not clinically relevant.
Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: May cause fetal CNS depression, hypotonia, and respiratory depression with chronic use. Avoid in pregnancy unless benefit outweighs risk.
Category B: No evidence of risk in humans. Cetirizine: no increased malformations in epidemiologic studies. Pseudoephedrine: potential risk of gastroschisis in first trimester; avoid first trimester. Second/third trimester: no known fetal risks; monitor for reduced uterine blood flow due to vasoconstriction.
Excreted in breast milk; M/P ratio 0.5-0.8. Potential for infant sedation and respiratory depression. Caution advised; monitor infant for drowsiness and feeding difficulties. Consider alternative therapies.
Small amounts excreted in breast milk. M/P ratio not established for combination. Cetirizine M/P ~0.25-1.3. Pseudoephedrine M/P ~2.6-3.5; may reduce milk production. Use with caution, especially in preterm infants. Monitor infant for irritability, sleep disturbance.
No standard dose adjustment recommended; however, increased clearance during pregnancy may necessitate higher doses for efficacy. Monitor therapeutic response and adjust as needed. Avoid use in first trimester if possible.
No pharmacokinetic changes requiring routine dose adjustment in pregnancy. However, increased renal clearance may reduce cetirizine levels; clinical significance unclear. Avoid excessive pseudoephedrine due to vasoconstriction; use lowest effective dose.
Amidate (etomidate) is an ultra-short acting non-barbiturate hypnotic used for induction of anesthesia and for procedural sedation. Key pearls: (1) Single dose causes adrenal suppression via 11β-hydroxylase inhibition; avoid continuous infusion or repeated doses. (2) Preferred for hemodynamically unstable patients due to minimal cardiovascular depression. (3) High incidence of myoclonus and pain on injection; pretreat with opioid or benzodiazepine to reduce myoclonus. (4) Contraindicated in porphyria. (5) Rapid onset (30-60 sec) and short duration (3-5 min) limit use to induction only.
Cetirizine/pseudoephedrine combines a second-generation antihistamine with a sympathomimetic decongestant. Avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Use caution in hyperthyroidism, diabetes, and prostate hyperplasia. Monitor for CNS stimulation (insomnia, nervousness) especially in evening dosing. Cetirizine is less sedating than first-generation antihistamines but may still cause drowsiness; pseudoephedrine can counteract sedation. Contraindicated with MAOIs or within 14 days of use. Not recommended in pregnancy category B (cetirizine) but pseudoephedrine crosses placenta; avoid in lactation.
This medication is given only by a healthcare professional in a hospital or clinic setting.,You may experience involuntary muscle movements (myoclonus) or pain at the injection site.,Tell your doctor if you have adrenal gland problems, porphyria, or if you are pregnant or breastfeeding.,The effects are short-lived; you will be monitored closely during and after administration.,Do not drive or operate machinery for at least 24 hours after receiving this medication.
Take this medication by mouth with or without food, with a full glass of water.,Do not crush or chew extended-release tablets; swallow whole.,Avoid alcohol, as it can increase drowsiness and side effects.,May cause drowsiness or dizziness; use caution when driving or operating machinery.,Do not exceed recommended dose; do not take more than every 12 hours.,Report rapid or irregular heartbeat, chest pain, or severe dizziness.,Discontinue use and consult doctor if symptoms persist after 7 days or with fever.,Avoid taking with other cold, allergy, or sleep aids without approval.,If you have high blood pressure, heart disease, or urinary retention, consult doctor before use.,Store at room temperature, away from moisture and heat.
No interactions on record
"Normethadone, an opioid analgesic with QT-prolonging properties, combined with cetirizine, a second-generation antihistamine that can also prolong the QT interval, increases the risk of additive cardiotoxicity, specifically potentially fatal ventricular arrhythmias like torsade de pointes. This interaction is most concerning in patients with preexisting QT prolongation, electrolyte disturbances, or those taking other QT-prolonging agents. Clinical outcomes may include palpitations, syncope, or sudden cardiac death."
"Cetirizine is a second-generation antihistamine that selectively blocks peripheral H1 receptors, while cyproheptadine is a first-generation antihistamine with additional antiserotonergic and anticholinergic properties. When coadministered, additive central nervous system depression may occur, leading to excessive sedation, dizziness, and psychomotor impairment. Concurrent use also potentiates anticholinergic adverse effects such as dry mouth, urinary retention, and blurred vision, particularly in elderly patients."
"Concurrent use of flupentixol and cetirizine may result in additive central nervous system depression, including increased sedation, drowsiness, and psychomotor impairment. Flupentixol, a thioxanthene antipsychotic with prominent antihistaminergic (H1) and antidopaminergic effects, combined with cetirizine, a peripheral H1-antihistamine with limited central penetration but dose-related sedative potential, can lead to exaggerated CNS and respiratory depression, altered cognitive function, and reduced reaction time. These effects increase the risk of falls, accidents, and respiratory compromise, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMIDATE vs CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, answered by our medical review team.
AMIDATE is a General Anesthetic that works by AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.. CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is a Sympathomimetic that works by Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction and decongestion of nasal mucosa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMIDATE and CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMIDATE is: 0.2-0.6 mg/kg IV bolus for induction of anesthesia.. The standard adult dose of CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is: 1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours; maximum 2 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMIDATE and CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMIDATE is classified as Category C. Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: . CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is classified as Category A/B. Category B: No evidence of risk in humans. Cetirizine: no increased malformations in epidemiologic studies. Pseudoephedrine: potential risk of gastroschisis in first trimester; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.